Everest Medicines (HKG: 1952) has announced the commercial launch of its Xerava (eravacycline) antibiotic in China, with the first prescription being administered at Huashan Hospital affiliated to Fudan University in Shanghai. This launch signifies the Chinese firm’s inaugural commercial-stage product release within the country.
Eravacycline: A Novel Intravenous Antibiotic for Multidrug-Resistant Infections
Eravacycline is a novel, fully synthetic, fluorocycline intravenous antibiotic designed for the treatment of infections caused by a range of susceptible gram-positive, gram-negative, and anaerobic pathogens, including those that are multidrug resistant (MDR). Currently, the product is approved for the treatment of complicated intra-abdominal infections in the US, EU, GB, Singapore, and mainland China. The medicine is also under review for community-acquired intra-abdominal infections (cIAI) in Taiwan. Eravacycline was licensed from Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of Innoviva, Inc.
Community-Acquired Intra-Abdominal Infections (cIAI) and Their Impact
cIAI is an infectious disease resulting from hospital or community-acquired infections that extend from hollow viscera to the peritoneal cavity, leading to peritonitis or abscess. The disease, which includes conditions such as abdominal abscess, gastric or intestinal perforation, peritonitis, appendicitis, cholecystitis, and diverticulitis, is caused by various pathogens, including gram-negative, gram-positive, and anaerobic bacteria. In 2018, approximately 2.9 million people in China were affected by this disease.
Partnership with Sinopharm Group Co., Ltd. for Distribution and Retailing
Everest Medicines has recently partnered with Sinopharm Group Co., Ltd. to capitalize on the latter’s supply chain service advantages in distribution, access, and retailing for Everest’s listed products in mainland China. This strategic collaboration aims to enhance the availability and accessibility of Xerava and other products within the Chinese market.-Fineline Info & Tech
